IDT and Cann Group Medicinal Cannabis Partnership
IDT Australia Limited (ASX: IDT) provides the following market update that it has entered into a manufacturing agreement with Cann Group Limited (ASX: CAN).
IDT has been contracted to provide manufacturing support in relation to medicinal cannabis‐based product formulations intended for supply to patients in Australia and overseas.
“Cann Group has established itself as an industry leading science‐based player in the quickly evolving Australian medicinal cannabis space, and we are delighted to be partnering with Cann Group to advance the development and supply of high-quality innovative product formulations.” said IDT’s CEO Dr David Sparling. “IDT’s manufacturing facilities are ideally suited to undertake this work and our track record in completing highly complex projects to global cGMP quality standards ensures we can add significant value to Cann’s development efforts.”
Cann Group CEO, Peter Crock, said: “IDT’s capabilities and experience in working with leading pharmaceutical companies made it an excellent manufacturing partner and we look forward to developing a range of delivery systems and dosage forms that can meet the varying needs of patients who can benefit from medicinal cannabis treatments.”